Senores Pharmaceuticals will hold an earnings conference call on July 27, 2026, to discuss the unaudited consolidated and standalone financial results for the quarter ended June 30, 2026. The call is scheduled to begin at 05:15 PM IST, providing investors and analysts an opportunity to review the company's performance for Q1FY27. The discussion will be led by the company's top management, including Mr. Swapnil Shah, Promoter and Managing Director, and Mr. Sanjay Majmudar, Chairman. Mr. Deval Shah, Whole-Time Director and Chief Financial Officer, will also be present to address queries regarding the financial statements.

The conference call is being facilitated by DAM Capital Advisors Ltd, with Nitin Agarwal serving as the analyst leading the session. Participants can join the discussion via universal access numbers provided for all networks and countries. The company has also released specific toll-free numbers for international participants across regions such as Hong Kong, Singapore, the UK, and the USA to ensure broad accessibility for global stakeholders.

Following the event, Senores Pharmaceuticals intends to publish an audio recording and a transcript of the conference call on its official website. This initiative is part of the company's compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring timely dissemination of material information to the market.

International Dial-in Details

The following toll-free numbers have been made available for international participants to join the earnings call:

Universal Access Numbers

Participants can dial +91 22 6280 1384 or +91 22 7115 8285 to connect to the call. The company has advised attendees to dial in at least 5-10 minutes prior to the scheduled start time to ensure a timely connection.

Senores Pharmaceuticals Limited has published its postal ballot notice in newspapers to seek shareholder approval for the variation in the utilisation of unutilised Initial Public Offer (IPO) proceeds amounting to ₹650.16 million. The company also seeks approval for material related party transactions (RPTs) aggregating ₹754 crore and an enhancement of limits for loans and guarantees under Sections 185 and 186 of the Companies Act, 2013. The voting process commences on July 05, 2026, and concludes on August 03, 2026.

The Board of Directors, based on the recommendation of the Audit Committee, approved the proposal to reallocate funds originally earmarked for setting up a sterile injections facility in Atlanta. The unutilised amount of ₹650.16 million will be redirected towards funding the acquisition of Abbreviated New Drug Applications (ANDAs) by subsidiary Senores Pharmaceuticals Inc. (SPI), and capital expenditure for subsidiaries Apnar Pharma Private Limited and Havix Group Inc. d/b/a Aavis Pharmaceuticals. The revised utilisation timelines extend to Q4 of FY 2028.

Shareholders will vote on eight resolutions, including five ordinary resolutions for RPTs with Havix Group Inc., Ratnatris Pharmaceuticals Private Limited, Apnar Pharma Private Limited, and transactions between fellow subsidiaries. The proposed RPTs for FY 2026-27 include transactions worth ₹337 crore with Havix Group Inc., ₹113 crore with Ratnatris Pharmaceuticals Private Limited, and ₹156 crore with Apnar Pharma Private Limited. The Audit Committee has reviewed and approved these transactions, confirming they will be conducted on an arm’s length basis.

Two special resolutions seek to enhance the existing limits for loans, guarantees, and investments. The company proposes to increase the limit under Section 185 to ₹750 crore and the limit under Section 186 to ₹750 crore, up from the previously approved ₹500 crore. These enhancements are intended to provide flexibility for future business requirements and strategic initiatives.

Postal Ballot Schedule

Proposed Reallocation of IPO Proceeds

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE0RB801010/eab6cb8701b44bb0.pdf